Citation Tools
PDFClinical/translational cancer immunotherapy
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial